DNLI
Denali Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$21.17
+8.83%Margins
Gross margin
-10.3%
EBITDA margin
-2347.4%
EBIT margin
-2488.1%
Net margin
-1470.5%
FCF margin
-2104.5%
-33.9%
Return on equity
-25.0%
Return on assets
-55.9%
Return on invested capital
0.02x
Asset turnover
-$444.2M
Cash from operations
$3.22
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Sep 1, 2026